X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (43) 43
female (42) 42
endocrinology & metabolism (41) 41
osteoporosis (39) 39
aged (34) 34
index medicus (33) 33
middle aged (32) 32
postmenopausal women (29) 29
denosumab (25) 25
bone density - drug effects (20) 20
osteoporosis, postmenopausal - drug therapy (20) 20
fractures (19) 19
aged, 80 and over (18) 18
alendronate (17) 17
bone mineral density (17) 17
bone density (16) 16
density (16) 16
strength (15) 15
analysis (13) 13
bones (13) 13
orthopedics (13) 13
bone density conservation agents - therapeutic use (12) 12
hip (12) 12
turnover (12) 12
bone resorption (11) 11
bone-mineral density (11) 11
hip fracture (11) 11
post-menopause (10) 10
tomography, x-ray computed (10) 10
absorptiometry, photon (9) 9
fracture (9) 9
monoclonal antibodies (9) 9
postmenopause (9) 9
adult (8) 8
antibodies, monoclonal - therapeutic use (8) 8
osteoclast differentiation (8) 8
osteogenesis (8) 8
risk (8) 8
antibodies, monoclonal - pharmacology (7) 7
antibodies, monoclonal, humanized (7) 7
bmd (7) 7
bone density conservation agents - pharmacology (7) 7
bone growth (7) 7
double-blind method (7) 7
femur (7) 7
romosozumab (7) 7
sost protein (7) 7
therapy (7) 7
vertebrae (7) 7
women (7) 7
antibodies, monoclonal, humanized - therapeutic use (6) 6
biochemical markers (6) 6
bone density conservation agents - administration & dosage (6) 6
bone remodeling - drug effects (6) 6
male (6) 6
mass (6) 6
mineral density (6) 6
osteoprotegerin ligand (6) 6
placebos (6) 6
postmenopausal osteoporosis (6) 6
prevention (6) 6
risk factors (6) 6
vertebral fractures (6) 6
absorptiometry, photon - methods (5) 5
alendronate - pharmacology (5) 5
antibodies, monoclonal - administration & dosage (5) 5
antibodies, monoclonal - adverse effects (5) 5
bone and bones - drug effects (5) 5
bone density conservation agents - adverse effects (5) 5
bone turnover markers (5) 5
clinical trials (5) 5
medicine, general & internal (5) 5
original (5) 5
osteoporosis, postmenopausal - diagnostic imaging (5) 5
osteoporosis, postmenopausal - metabolism (5) 5
ovariectomized cynomolgus monkeys (5) 5
quantitative computed-tomography (5) 5
time factors (5) 5
age (4) 4
anabolics (4) 4
animals (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
biomarkers - blood (4) 4
bone (4) 4
bone mass (4) 4
comparative analysis (4) 4
hormone replacement therapy (4) 4
obesity - physiopathology (4) 4
osteoporosis - drug therapy (4) 4
quantitative computed tomography (4) 4
rank ligand - antagonists & inhibitors (4) 4
rank ligand - pharmacology (4) 4
risedronate (4) 4
sclerostin (4) 4
spine (4) 4
teriparatide (4) 4
trabecular bone (4) 4
trial (4) 4
abridged index medicus (3) 3
alendronate - therapeutic use (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Bone and Mineral Research, ISSN 0884-0431, 01/2015, Volume 30, Issue 1, pp. 46 - 54
Journal Article
Journal of Clinical Densitometry, ISSN 1094-6950, 2008, Volume 11, Issue 3, pp. 456 - 456
Journal Article
Journal Article
Journal of Clinical Densitometry, ISSN 1094-6950, 2013, Volume 16, Issue 2, pp. 250 - 256
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 3/2012, Volume 27, Issue 3, pp. 694 - 701
The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for the treatment of postmenopausal women with osteoporosis.... 
PIVOTAL FRACTURE TRIAL EXTENSION | FRACTURE | BONE MINERAL DENSITY | DENOSUMAB | Original | BONE TURNOVER MARKERS
Journal Article
Journal of Bone and Joint Surgery, ISSN 0021-9355, 2012, Volume 94, Issue 23, pp. 2113 - 2119
Background Fracture is the major complication of osteoporosis, and it allows the identification of individuals needing medical intervention for osteoporosis.... 
Orthopedics
Journal Article
Journal of Clinical Densitometry, ISSN 1094-6950, 04/2013, Volume 16, Issue 2, pp. 147 - 153
Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced... 
Journal Article
Journal of Clinical Densitometry, ISSN 1094-6950, 04/2013, Volume 16, Issue 2, pp. 250 - 256
FREEDOM was a phase 3 trial in 7808 women aged 60a90 yr with postmenopausal osteoporosis. Subjects received placebo or 60 mg denosumab subcutaneously every 6... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.